Does DURVALUMAB Cause Neoplasm recurrence? 8 Reports in FDA Database
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 8 reports of Neoplasm recurrence have been filed in association with DURVALUMAB (IMFINZI). This represents 0.1% of all adverse event reports for DURVALUMAB.
8
Reports of Neoplasm recurrence with DURVALUMAB
0.1%
of all DURVALUMAB reports
4
Deaths
2
Hospitalizations
How Dangerous Is Neoplasm recurrence From DURVALUMAB?
Of the 8 reports, 4 (50.0%) resulted in death, 2 (25.0%) required hospitalization.
Is Neoplasm recurrence Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for DURVALUMAB. However, 8 reports have been filed with the FAERS database.
What Other Side Effects Does DURVALUMAB Cause?
Death (2,817)
Malignant neoplasm progression (1,330)
Pneumonitis (827)
Radiation pneumonitis (786)
Pyrexia (573)
Diarrhoea (530)
Pneumonia (453)
Dyspnoea (444)
Interstitial lung disease (430)
Off label use (395)
What Other Drugs Cause Neoplasm recurrence?
CYCLOPHOSPHAMIDE (293)
PALBOCICLIB (248)
DOXORUBICIN (240)
VINCRISTINE (239)
CYTARABINE (223)
METHOTREXATE (198)
CARBOPLATIN (170)
RITUXIMAB (163)
ETOPOSIDE (156)
PREDNISONE (144)
Which DURVALUMAB Alternatives Have Lower Neoplasm recurrence Risk?
DURVALUMAB vs DUTASTERIDE
DURVALUMAB vs DUTASTERIDE\TAMSULOSIN
DURVALUMAB vs DUVELISIB
DURVALUMAB vs DYDROGESTERONE
DURVALUMAB vs EBASTINE